HMGB1 and Alzheimer disease: We, therefore, hypothesize that the release of HMGB1 during the formation of NETs may exacerbate neuroinflammation and that HMGB1-targeted therapy may, therefore, be beneficial in neutrophil-associated inflammatory conditions, such that blocking the activity of this protein may also offer a new therapeutic approach to AD.